Seroatlas · Human Serome Atlas

TAS2R13

Taste receptor type 2 member 13

Also known as: T2R13, T2R13_HUMAN, TRB3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NYV9
Gene: TAS2R13
Ensembl: ENSG00000212128
Chromosome: 12
Canonical length: 303 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

This gene product belongs to the family of candidate taste receptors that are members of the G-protein-coupled receptor superfamily. These proteins are specifically expressed in the taste receptor cells of the tongue and palate epithelia. They are organized in the genome in clusters and are genetically linked to loci that influence bitter perception in mice and humans. In functional expression studies, they respond to bitter tastants. This gene maps to the taste receptor gene cluster on chromosome 12p13. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

303 residues, UniProt reviewed canonical sequence.

>Q9NYV9|TAS2R13
     1  MESALPSIFT LVIIAEFIIG NLSNGFIVLI NCIDWVSKRE LSSVDKLLII LAISRIGLIW
    61  EILVSWFLAL HYLAIFVSGT GLRIMIFSWI VSNHFNLWLA TIFSIFYLLK IASFSSPAFL
   121  YLKWRVNKVI LMILLGTLVF LFLNLIQINM HIKDWLDRYE RNTTWNFSMS DFETFSVSVK
   181  FTMTMFSLTP FTVAFISFLL LIFSLQKHLQ KMQLNYKGHR DPRTKVHTNA LKIVISFLLF
   241  YASFFLCVLI SWISELYQNT VIYMLCETIG VFSPSSHSFL LILGNAKLRQ AFLLVAAKVW
   301  AKR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TAS2R13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 0 nTPM

Expression across tissuesHPA

Tissue

adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM
blood vessel: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

white matter: 2.6 nTPM
cerebellum: 2.2 nTPM
cerebral cortex: 2.2 nTPM
hypothalamus: 2.1 nTPM
medulla oblongata: 2.1 nTPM
pons: 2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD missense Z: -1.04
DepMap mean gene effect: 0.09
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TAS2R13 as an antibody target. Whether an autoantibody or antibody against TAS2R13 could matter depends on whether native TAS2R13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TAS2R13 is annotated at the cell surface, where native TAS2R13 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TAS2R13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...